Intech Investment Management LLC Buys 3,038 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Intech Investment Management LLC increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 195,587 shares of the biopharmaceutical company’s stock after purchasing an additional 3,038 shares during the quarter. Intech Investment Management LLC’s holdings in Gilead Sciences were worth $18,066,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the business. State Street Corp grew its position in Gilead Sciences by 1.4% in the 3rd quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company’s stock valued at $5,044,795,000 after acquiring an additional 841,776 shares during the last quarter. Wellington Management Group LLP grew its position in Gilead Sciences by 50.9% in the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock valued at $2,900,921,000 after acquiring an additional 11,665,593 shares during the last quarter. FMR LLC grew its position in Gilead Sciences by 79.4% in the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock valued at $2,780,329,000 after acquiring an additional 14,680,161 shares during the last quarter. Geode Capital Management LLC grew its position in Gilead Sciences by 2.1% in the 3rd quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company’s stock valued at $2,302,119,000 after acquiring an additional 574,421 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Gilead Sciences by 3.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 8,002,779 shares of the biopharmaceutical company’s stock worth $739,217,000 after buying an additional 249,804 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 0.7 %

Shares of GILD stock opened at $112.26 on Tuesday. The firm has a market capitalization of $139.80 billion, a PE ratio of 303.41, a P/E/G ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The stock’s 50-day simple moving average is $102.24 and its 200-day simple moving average is $93.16. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.81%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is 854.05%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders have sold 302,785 shares of company stock valued at $30,503,250. Company insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the topic of a number of recent research reports. Wells Fargo & Company increased their price target on Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Daiwa America raised Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Royal Bank of Canada increased their price target on Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a “hold” rating to a “buy” rating and upped their price objective for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. Finally, Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $104.52.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.